Validation of three staging systems for hepatocellular carcinoma (JIS score, biomarker-combined JIS score and BCLC system) in 4,649 cases from a Japanese nationwide survey

Digestive Diseases

Volumn 32, Issue 6, 2014, Pages 717-724

  Kitai, Satoshi ^a   Kudo, Masatoshi ^a   Izumi, Namiki ^b   Kaneko, Shuichi ^c   Ku, Yonson ^d   Kokudo, Norihiro ^e   Sakamoto, Michiie ^f   Takayama, Tadatoshi ^g   Nakashima, Osamu ^h   Kadoya, Masumi ⁱ   Matsuyama, Yutaka ^j   Matsunaga, Takashi ^k  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b MUSASHINO RED CROSS HOSPITAL   (Japan)

^c KANAZAWA UNIVERSITY HOSPITAL   (Japan)

^d KOBE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^e Artificial Organ and Transplantation Division   (Japan)

^f KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^g NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h KURUME UNIVERSITY HOSPITAL   (Japan)

ⁱ SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^j UNIVERSITY OF TOKYO   (Japan)

^k OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ABLATION THERAPY; AGED; ALPHA FETOPROTEIN BLOOD LEVEL; BARCELONA CLINIC LIVER CANCER STAGING SYSTEM; BIOMARKER COMBINED JAPAN INTEGRATED STAGING SCORE; CANCER DIAGNOSIS; CANCER GRADING; CANCER PATIENT; CANCER PROGNOSIS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; CONFERENCE PAPER; CONTROLLED STUDY; CONVENTIONAL JAPAN INTEGRATED STAGING SCORE; FEMALE; FOLLOW UP; HEPATITIS C VIRUS; HUMAN; JAPANESE (PEOPLE); LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; NAMED INVENTORIES, QUESTIONNAIRES AND RATING SCALES; OVERALL SURVIVAL; SEX RATIO; SURVIVAL TIME; TUMOR INVASION; TUMOR VOLUME; ADULT; ANALYSIS OF VARIANCE; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DISEASE FREE SURVIVAL; FACTUAL DATABASE; IMMUNOHISTOCHEMISTRY; JAPAN; LIVER TUMOR; METABOLISM; MIDDLE AGED; MORTALITY; MULTIVARIATE ANALYSIS; NEEDLE BIOPSY; PATHOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS; SPAIN; SURVIVAL; VALIDATION STUDY;

ADULT; AGED; ALPHA-FETOPROTEINS; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; BIOPSY, NEEDLE; CARCINOMA, HEPATOCELLULAR; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; LIVER NEOPLASMS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SPAIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84910614641     PISSN: 02572753     EISSN: 14219875     Source Type: Journal    
DOI: 10.1159/000368008     Document Type: Conference Paper

References (30)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011;61:69-90.
2. Kim DY, Han KH: Epidemiology and surveillance of hepatocellular carcinoma. Liver Cancer 2012;1:2-14.
3. Llovet JM, Bru C, Bruix J: Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999;19:329-338.
4. Kudo M, Chung H, Osaki Y: Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan Integrated Staging Score (JIS score). J Gastroenterol 2003;38:207-215.
5. Kitai S, Kudo M, Minami Y, Ueshima K, Chung H, Hagiwara S, Inoue T, Ishikawa E, Takahashi S, Asakuma Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: A new prognostic staging system for hepatocellular carcinoma: value of the biomarker combined Japan integrated staging score. Intervirology 2008;51(suppl 1):86-94.
6. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology 1998;28:751-755.
7. Chevret S, Trinchet JC, Mathieu D, Rached AA, Beaugrand M, Chastang C: A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol 1999;31:133-141.
8. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012;379:1245-1255.
9. Leung TW, Tang AM, Zee B, Lau WY, Lai PB, Leung KL, Lau JT, Yu SC, Johnson PJ: Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging system: a study based on 926 patients. Cancer 2002;94:1760-1769.
10. The Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer (ed 5, revised, in Japanese). Tokyo, Kanehara, 2009.
11. Kudo M, Chung H, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: the JIS score compared with the CLIP score. Hepatology 2004;40:1396-1405.
12. Toyoda H, Kumada T, Kiriyama S, Sone Y, Tanikawa M, Hisanaga Y, Yamaguchi A, Isogai M, Kaneoka Y, Washizu J: Comparison of the usefulness of three staging systems for hepatocellular carcinoma (CLIP, BCLC, and JIS) in Japan. Am J Gastroenterol 2005;100:1764-1771.
13. Kondo K, Chijiiwa K, Nagano M, Hiyoshi M, Kai M, Maehara N, Ohuchida J, Nakao H, Ohkuwa Y: Comparison of seven prognostic staging systems in patients who undergo hepatectomy for hepatocellular carcinoma. Hepatogastroenterology 2007;54:1534-1538.
14. Chung H, Kudo M, Takahashi S, Hagiwara S, Sakaguchi Y, Inoue T, Minami Y, Ueshima K, Fukunaga T, Matsunaga T: Comparison of three current staging systems for hepatocellular carcinoma: Japan integrated staging score, new Barcelona Clinic Liver Cancer staging classification, and Tokyo score. J Gastroenterol Hepatol 2008;23:445-452.
15. Song P, Gao J, Inagaki Y, Kokudo N, Hasegawa K, Sugawara Y, Tang W: Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and China. Liver Cancer 2013;2:31-39.
16. Kudo M: Alpha-fetoprotein-L3: useful or useless for hepatocellular carcinoma? Liver Cancer 2013;2:151-152.
17. Toyoda H, Kumada T, Osaki Y, Oka H, Urano F, Kudo M, Matsunaga T: Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 2006;4:1528-1536.
18. Akaike H: A new look at statistical model identification. IEEE Trans Automat Contr 1974;19:716-722.
19. Oka H, Tamori A, Kuroki T, Kobayashi K, Yamamoto S: Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 1994;19:61-66.
20. Riaz A, Ryu RK, Kulik LM, Mulcahy MF, Lewandowski RJ, Minocha J, Ibrahim SM, Sato KT, Baker T, Miller FH, Newman S, Omary R, Abecassis M, Benson AB 3rd, Salem R: Alphafetoprotein response after locoregional therapy for hepatocellular carcinoma: oncologic marker of radiologic response, progression, and survival. J Clin Oncol 2009;27:5734-5742.
21. Shao YY, Hsu CH, Cheng AL: Predictive biomarkers of antiangiogenic therapy for advanced hepatocellular carcinoma: where are we? Liver Cancer 2013;2:93-107.
22. Tamura Y, Igarashi M, Suda T, Wakai T, Shirai Y, Umemura T, Tanaka E, Kakizaki S, Takagi H, Hiasa Y, Onji M, Aoyagi Y: Fucosylated fraction of alpha-fetoprotein as a predictor of prognosis in patients with hepatocellular carcinoma after curative treatment. Dig Dis Sci 2010;55:2095-2101.
23. Yamashita Y, Tsuijita E, Takeishi K, Fujiwara M, Kira S, Mori M, Aishima S, Taketomi A, Shirabe K, Ishida T, Maehara Y: Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol 2012;19:2027-2034.
24. Hamamura K, Shiratori Y, Shiina S, Imamura M, Obi S, Sato S, Yoshida H, Omata M: Unique clinical characteristics of patients with hepatocellular carcinoma who present with high plasma des-gamma-carboxy prothrombin and low serum alpha-fetoprotein. Cancer 2000;88:1557-1564.
25. Kitai S, Kudo M, Minami Y, Haji S, Osaki Y, Oka H, Seki T, Kasugai H, Sasaki Y, Matsunaga T: Validation of a new prognostic staging system for hepatocellular carcinoma: A comparison of the biomarker-combined Japan Integrated Staging Score, the conventional Japan Integrated Staging Score and the BALAD Score. Oncology 2008;75(suppl 1):83-90.
26. Nouso K, Ito Y, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, Yamamoto K: Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008;98:1161-1165.
27. Kudo M, Osaki Y, Matsunaga T, Kasugai H, Oka H, Seki T: Hepatocellular carcinoma in Child-Pugh C cirrhosis: prognostic factors and survival benefit of nontransplant treatments. Dig Dis 2013;31:490-498.
28. Kudo M, Izumi N, Kokudo N, Matsui O, Sakamoto M, Nakashima O, Kojiro M, Makuuchi M: Management of hepatocellular carcinoma in Japan: Consensus-based clinical practice guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Dig Dis 2011;29:339-364.
29. Yamashita F, Tanaka M, Satomura S, Tanikawa K: Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinomas. Gastroenterology 1996;111:996-1001.
30. Koike Y, Shiratori Y, Sato S, Obi S, Teratani T, Imamura M, Yoshida H, Shiina S, Omata M: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.